Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects

发表于 2026-7-6 11:36:31

期刊：Expert Opinion on Investigational Drugs

文献作者：Siyi Wang; Xiaoyan Yang; Jie Huang; Shuang Yang; Qian Wu; Honghui Chen; Shuting Wu; Changlin Dou; Guoping Yang; Yuxia Xiang

出版日期：2022-10-3

DOI号：10.1080/13543784.2022.2120389

下载链接：https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2120389

文献链接：https://doi.org/10.1080/13543784.2022.2120389

当前文献来源于 Informa UK Limited。

备注信息：

发表于 2026-7-6 11:36:32

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[taylor&francis] Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[taylor&francis] Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects 一键复制